



Marco Bollier

Chief Commercial Officer, Geistlich Pharma China & Board member of SwissCham Beijing

Graduated with a Master's degree in Law from the University of St. Gallen. Extensive experience in Market & Business Development operations for Swiss Med Tech companies in Asia (from solving regulatory issues in China to setting up subsidiary in India). Lived and worked in China for more than 8 years. Currently working as Chief Commercial Officer of Geistlich Pharma (Global market leader for regenerative Biomaterials) in Beijing. Also serving as a Member of the Board of Directors in the Swiss Chamber of Commerce in China.



Nils Eckardt, M.D., M.Sc.

VP, Medical Affairs, Europe

Nils Eckardt, M.D., M.Sc. joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe, responsible for building the medical affairs organization across Europe and providing strategic and scientific guidance. Prior to joining BeiGene, Dr. Eckardt served most recently as Vice President and Head of International Medical Affairs at Tesaro and as Head of Medical Affairs Europe at Ariad Pharmaceuticals before that. Previously, he spent more than 10 years at Roche in multiple positions of increasing responsibility within the medical affairs organization. Dr. Eckardt has launched six drugs in nine indications throughout his career. He received an M.D. from the Georg August University of Göttingen and completed a postdoctoral master's degree in Medical Sciences Clinical Pharmacology at the University of Glasgow.



Jessica Liu

Vice President, Head of International Business, Tigermed

Dr. Liu is currently the VP and Head of International Business Department of Tigermed Co. Ltd, the leading CRO in China. She is focusing on business operation expansion to the oversea market and integration of clinical operations across the different countries, including but not only limited to US, Europe, Korea, Japan, Taiwan, Hong Kong, and Southeast Asia. She was also acting CEO of DCIS, a Tigermed Company in Korea as one of biggest domestic CROs. on May22,2020,DCIS was successfully listed in KSDAQ as the very first and only listed clinical CRO in Korea stock market. Jessica has 26 years of cumulative experience in clinical research and development in global pharmaceutical companies and global CRO companies: (1994-1997 Roche, 1997-2008 BMS, 2009-2016 MDS-INC Research). Her special skill set is bridging the culture difference and working practice gap between China/Asia to the western world.



Jinyi Li

Head of Forecasting and Supply Pharma, Roche China

Jinyi Li, current Head of Forecasting & Supply China, is leading Sales Forecasting, Replenishment Planning and Supply team at Roche Pharma China. Jinyi has been working in the Pharmaceutical industry for 14 years. She joined Roche Pharma in 2012. Since then, she has held various roles with growing responsibilities in area of Global Supply Chain, Global Strategic Planning and Global Engineering. While facing the challenging supply situation during the COVID19, Jinyi led the COVID19 China Product Supply Task Force team to ensure business continuity and continuous supply of medicines for patients in China. She has provided leadership and coaching for the supply risk management through difficult times.



Christophe Weber

Secretary General, BCGE

President, Swiss-Chinese Chamber of Commerce Geneva Chapter

1998-2000, MA in Economics and Communication Studies, University of California Los Angeles (UCLA); 2000-2002, MA in Political Sciences and International Relations, University of Geneva; 2011-2012, EMBA INSEAD/Tsinghua; 2000-03, Political Adviser and Legislative Assistant at the Swiss National Council, focusing on public policy efficiency, monetary policy and foreign policy; with World Economic Forum: 2003-07, Head of Government Relations; 2007-08, Head of Europe and Central Asia; 2008-12, Executive Director - Head of Greater China and Chief Representative, Beijing, China. Currently, Company Secretary of the State Bank of Geneva (BCGE), responsible for overseeing the operational delivery of Group Communications and Marketing, Group Human Resources, Group Legal Services and Group Strategy reporting to Chief Executive Officer. 2010-2012, Director of the Board of the Swiss Chinese Chamber in Commerce in Beijing; 2008-2012, President of the Board of the Swiss Chinese Chamber of Commerce (Geneva Chapter) 2017-now; Expertise: business development, strategy, corporate affairs.



Moderator: Fiona Gao

Attorney-at-law (New York), Senior Associate & Manager of China Life Sciences Group, VISCHER AG

Fiona focuses on cross-border transactions (foreign direct investment, M&A, corporate and commercial) and Life Sciences. She advises Swiss and international clients, in particular Chinese clients, of all sizes.

With over 10 years of multi-jurisdictional (China, Switzerland, U.S.) legal advisory experiences in leading law firms and in in-house team of multinational companies, she brings a unique and comprehensive legal expertise to Sino-Swiss clients.

Combining her legal and industry expertise, she counsels and guides Chinese and Swiss Life Sciences companies in cross-border investment and collaboration.